Home Newsfeeds Keybanc Initiates Coverage On Allbirds with Sector Weight Rating

Keybanc Initiates Coverage On Allbirds with Sector Weight Rating

Keybanc analyst Noah Zatzkin initiates coverage on Allbirds (NASDAQ:BIRD) with a Sector Weight rating.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Keybanc analyst Noah Zatzkin initiates coverage on Allbirds (NASDAQ:BIRD) with a Sector Weight rating.

Synaptics Gets Price Target Cuts From Analysts After Q3 Results

By Lisa Levin

May 4, 3:26 PM

Synaptics Incorporated (NASDAQ: SYNA) reported better-than-expected earnings for its third quarter.

SYNA

Score Big With Microsoft Store’s Ultimate Game Sale: Huge Savings On FIFA 23, Star Wars Jedi: Survivor, Elden Ring

By Franca Quarneti

July 17, 12:32 PM

Microsoft Corp. (NASDAQ: MSFT) Microsoft Store launched its Ultimate Game Sale, offering exciting deals on select Xbox and PC games, PC accessories and Xbox console bundles.

ATVI

After China Setback, Nvidia CEO Says AI Chipmaker To ‘Deepen’ Ties With This Southeast Asian Nation: ‘We Have Millions Of Clients Here’

By Shanthi Rexaline

December 11, 5:02 AM

Nvidia has so far invested $250 million in Vietnam, partnering with leading tech companies to deploy AI across industries.

NVDA

One Good, One Bad News For Bristol Myers Squibb’s Marketed Drugs: Details

By Vandana Singh

April 1, 9:44 AM

Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati (adagrasib) in KRASG12C-mutated NSCLC.

BMY

Keybanc Initiates Coverage On Allbirds with Sector Weight Rating

Related Posts

Synaptics Gets Price Target Cuts From Analysts After Q3 Results

Score Big With Microsoft Store’s Ultimate Game Sale: Huge Savings On FIFA 23, Star Wars Jedi: Survivor, Elden Ring

After China Setback, Nvidia CEO Says AI Chipmaker To ‘Deepen’ Ties With This Southeast Asian Nation: ‘We Have Millions Of Clients Here’

One Good, One Bad News For Bristol Myers Squibb’s Marketed Drugs: Details